• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Metsera Inc.

    6/3/25 4:30:15 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTSR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Metsera, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    59267L107

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    59267L107


    1Names of Reporting Persons

    Validae Health, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    12,767,462.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    12,767,462.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,767,462.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    59267L107


    1Names of Reporting Persons

    Population Health Partners GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    12,767,462.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    12,767,462.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,767,462.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.2 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Limited Liability Company


    SCHEDULE 13G

    CUSIP No.
    59267L107


    1Names of Reporting Persons

    Christopher Whitten Bernard
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    369,182.00
    6Shared Voting Power

    12,767,462.00
    7Sole Dispositive Power

    369,182.00
    8Shared Dispositive Power

    12,767,462.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    13,136,644.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.5 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    59267L107


    1Names of Reporting Persons

    Christopher T. Cox
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    18,914.00
    6Shared Voting Power

    12,767,462.00
    7Sole Dispositive Power

    18,914.00
    8Shared Dispositive Power

    12,767,462.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,786,376.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.2 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    59267L107


    1Names of Reporting Persons

    Clive A. Meanwell
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    67,438.00
    6Shared Voting Power

    12,767,462.00
    7Sole Dispositive Power

    67,438.00
    8Shared Dispositive Power

    12,767,462.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,834,900.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.2 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Metsera, Inc.
    (b)Address of issuer's principal executive offices:

    3 World Trade Center, 175 Greenwich Street, New York, NY, 10007
    Item 2. 
    (a)Name of person filing:

    Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of: Validae Health, L.P. Population Health Partners GP, LLC Christopher Whitten Bernard Christopher T. Cox Clive A. Meanwell
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of the Reporting Persons is c/o Population Health Partners, L.P., 1200 Morris Turnpike, Suite 3005, Short Hills, NJ 07078.
    (c)Citizenship:

    Validae Health, L.P. and Population Health Partners GP, LLC are organized under the laws of the State of Delaware. Clive A. Meanwell is a citizen of the United Kingdom. The remaining Reporting Persons are citizens of the United States.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    59267L107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information contained on the cover pages to this Schedule 13G is incorporated by reference into this Item 4. The ownership information presented herein represents beneficial ownership of Common Stock as of the date of this filing, based upon 105,055,538 shares of Common Stock outstanding as of May 6, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 12, 2025. Validae Health, L.P. is the record holder 12,767,462 shares of Common Stock. Population Health Partners GP, LLC ("PHP GP LLC"), is the sole general partner of Validae Health, L.P., and may be deemed to beneficially own the shares of Common Stock held by Validae Health, L.P. Christopher Whitten Bernard, Christopher T. Cox and Clive A. Meanwell are members of PHP GP LLC and may be deemed to share the power to direct the disposition and vote of the shares held by Validae Health, L.P. Additionally, Christopher Whitten Bernard is the beneficial owner of 369,182 shares of Common Stock underlying stock options that are vested or will vest within 60 days of the date hereof, Christopher T. Cox is the beneficial owner of 18,914 shares of Common Stock underlying stock options that are vested or will vest within 60 days of the date hereof and Clive A. Meanwell is the beneficial owner of 67,438 shares of Common Stock underlying stock options that are vested or will vest within 60 days of the date hereof.
    (b)Percent of class:

    See cover pages
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See cover pages

     (ii) Shared power to vote or to direct the vote:

    See cover pages

     (iii) Sole power to dispose or to direct the disposition of:

    See cover pages

     (iv) Shared power to dispose or to direct the disposition of:

    See cover pages

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Validae Health, L.P.
     
    Signature:/s/ Christopher Cox
    Name/Title:Christopher Cox, President
    Date:06/03/2025
     
    Population Health Partners GP, LLC
     
    Signature:/s/ Christopher Cox
    Name/Title:Christopher Cox, Member
    Date:06/03/2025
     
    Christopher Whitten Bernard
     
    Signature:/s/ Christopher Whitten Bernard
    Name/Title:Christopher Whitten Bernard
    Date:06/03/2025
     
    Christopher T. Cox
     
    Signature:/s/ Christopher T. Cox
    Name/Title:Christopher T. Cox
    Date:06/03/2025
     
    Clive A. Meanwell
     
    Signature:/s/ Clive A. Meanwell
    Name/Title:Clive A. Meanwell
    Date:06/03/2025
    Exhibit Information

    Exhibit 99: Joint Filing Agreement

    Get the next $MTSR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTSR

    DatePrice TargetRatingAnalyst
    9/9/2025$77.00Outperform
    Leerink Partners
    6/20/2025$65.00Overweight
    Wells Fargo
    2/25/2025$56.00Buy
    Guggenheim
    2/25/2025$38.00Buy
    BofA Securities
    2/25/2025Outperform
    Evercore ISI
    More analyst ratings

    $MTSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3

    Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting High study and treatment retention in both VESPER-1 and VESPER-3 trials Data support Phase 3 initiation in late 2025 NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ: MTSR), today announced positive topline data from VESPER-1 and positive data from a planned interim analysis for tolerability of VESPER-3 – two Phase 2b trials of MET-097i, a first-in-class fully biased, ultra-long acting GLP-1 receptor agonist (RA) with potential for monthly dosing. In VESPER-1, MET-097i demonstrated me

    9/29/25 4:01:13 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

    Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer's pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an initial enterprise value of $4.9 billion with a CVR of up to $22.50 per share in additional payments Pfizer to host a public webcast at 8 am EDT today Pfizer Inc. (NYSE:PFE) and Metsera, Inc. (NASDAQ:MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a

    9/22/25 6:45:00 AM ET
    $MTSR
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting

    NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will present clinical and preclinical data from its portfolio of next-generation ultra-long acting, scalable, and combinable therapies at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) held September 15-19, 2025, in Vienna, Austria. "As we progress our pipeline of ultra-long acting next-generation nutrient-stimulated hormone, or NuSH, therapies, we are encouraged by the opportunity to leverage our investigational medicines both as monotherapies and in comb

    9/11/25 7:00:53 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Metsera with a new price target

    Leerink Partners initiated coverage of Metsera with a rating of Outperform and set a new price target of $77.00

    9/9/25 7:59:28 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Metsera with a new price target

    Wells Fargo initiated coverage of Metsera with a rating of Overweight and set a new price target of $65.00

    6/20/25 7:54:18 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Metsera with a new price target

    Guggenheim initiated coverage of Metsera with a rating of Buy and set a new price target of $56.00

    2/25/25 7:57:00 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: See Remark 1 Fmr Llc acquired 1,107,547 shares (SEC Form 4)

    4/A - Metsera, Inc. (0002040807) (Issuer)

    9/12/25 4:09:01 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    See Remark 1 Fmr Llc sold $9,648 worth of shares (268 units at $36.00), disposed of 2,367,294 shares, acquired 2,151,820 shares and acquired 895 shares (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    9/4/25 2:58:55 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pinto Joshua

    4 - Metsera, Inc. (0002040807) (Issuer)

    5/22/25 7:42:42 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    SEC Filings

    View All

    Metsera Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Metsera, Inc. (0002040807) (Filer)

    9/29/25 5:16:53 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Metsera Inc.

    8-K - Metsera, Inc. (0002040807) (Filer)

    9/22/25 7:41:54 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Metsera Inc.

    10-Q - Metsera, Inc. (0002040807) (Filer)

    7/28/25 4:20:51 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Burow Kristina converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:15:35 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Berns Paul L bought $14,219,964 worth of shares (789,998 units at $18.00) and converted options into 7,523,682 shares (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:04:05 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Arch Venture Partners Xii, Llc converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:01:33 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Financials

    Live finance-specific insights

    View All

    Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

    Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer's pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an initial enterprise value of $4.9 billion with a CVR of up to $22.50 per share in additional payments Pfizer to host a public webcast at 8 am EDT today Pfizer Inc. (NYSE:PFE) and Metsera, Inc. (NASDAQ:MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a

    9/22/25 6:45:00 AM ET
    $MTSR
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

    Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placeb

    6/9/25 7:00:00 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care